Source-grounded facts extracted from Pediatrix Medical Group, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Pediatrix Medical Group, Inc. reported three months ended March 31, 2026 results: revenue $476 million, net income $30 million, EPS $0.36 per share. Guidance reaffirmed.
“ended March 31, 2026. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.44. For the 2026 first quarter, Pediatrix reported the following results: • Net revenue of $476 million; • Net income of $30 million; and • Adjusted EBITDA of $58 million. “Our first quarter operating results exceeded our expectations, driven by top-line growth,” said Mark S.”
Dr. James D. Swift departed as other_named_officer at Pediatrix Medical Group, Inc..
“succeeding Dr. James D. Swift.”
Mark S. Ordan was appointed as Chief Executive Officer at Pediatrix Medical Group, Inc..
“appointed Mr. Mark S. Ordan to serve as the Company’s Chief Executive Officer and principal executive officer, succeeding Dr. James D. Swift.”
Curtis B. Pickert changed role as Executive Vice President, Chief Physician Executive at Pediatrix Medical Group, Inc..
“the Company announced that Curtis B. Pickert, M.D. has transitioned from his role as the Company’s Executive Vice President, Chief Operating Officer and will now serve as Pediatrix’s Executive Vice President, Chief Physician Executive, effective as of August 1, 2024.”
Mary Ann E. Moore was appointed as Chief Administrative Officer at Pediatrix Medical Group, Inc..
“The Company also announced that the Board has appointed Ms. Mary Ann E. Moore to serve as the Company’s Chief Administrative Officer, in addition to her existing roles as the Company’s Executive Vice President, General Counsel and Secretary, effective as of August 1, 2024.”
Kasandra Rossi was appointed as Executive Vice President, Chief Financial Officer and Treasurer at Pediatrix Medical Group, Inc..
“On August 6, 2024, the Company announced that its board of directors (the “Board”) has appointed Ms. Kasandra Rossi, who currently serves as the Company’s Senior Vice President, Financial Reporting and Assistant Treasurer, to succeed Mr. C. Marc Richards as Executive Vice President, Chief Financial Officer (“CFO”) and Treasurer of the Company.”
C. Marc Richards was terminated as Executive Vice President, Chief Financial Officer and Treasurer at Pediatrix Medical Group, Inc..
“Mr. Richards’ transition from his role as Executive Vice President, CFO and Treasurer is a termination without “Cause” pursuant to that certain Amended and Restated Employment Agreement”
Lee A. Wood departed as Executive Vice President, National and Market Operations at Pediatrix Medical Group, Inc..
“On June 17, 2024, Pediatrix Medical Group, Inc., a Florida corporation (the “Company”), notified Mr. Lee. A Wood that the Company was eliminating the role of Executive Vice President, National and Market Operations, effective as of July 5, 2024 (the “Effective Date”), as part of the Company’s previously announced continued focus on operating efficiency.”
Earnings Releases
Pediatrix Medical Group, Inc. reported the three months ended March 31, 2024 results: revenue $495.1 million, net income $4.0 million, EPS $0.05 per diluted share. Guidance reaffirmed.
“ended March 31, 2024. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.20. For the 2024 first quarter, Pediatrix reported the following results: • Net revenue of $495 million; • Net income of $4 million; and • Adjusted EBITDA of $37 million. “Our first quarter operating results were in line with our expectations,” said James D. Swift, M.D., Chief”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.